FDA ends for now use of two monoclonal antibodies, spurring a halt in federal shipments of the covid-19 treatments

Posted on AllSides January 24th, 2022
From The Left
Joe Raedle/Getty Images

The Food and Drug Administration on Monday took two monoclonal antibody therapies off the list of covid-19 treatments for now, saying the medications should not be used anywhere in the United States because they are ineffective against the dominant omicron variant.

As a result, the Biden administration said it will pause distribution of the therapies, manufactured by Regeneron Pharmaceuticals and Eli Lilly, to the states.

Read full story
Some content from this outlet may be limited or behind a paywall.

More News about Public Health from the Left, Center and Right

From the Left

From the Center

From the Right